Literature DB >> 12410584

Effect of ABO blood group on the collagen-binding assay for von Willebrand factor.

Erin Haley1, Nadiya Babar, Cory Ritter, Katharine A Downes, Deana Green, Susan Shurin, Ravindra Sarode.   

Abstract

von Willebrand disease (VWD) is the most common congenital bleeding disorder and is caused by a quantitative or qualitative abnormality of von Willebrand factor (VWF). Ristocetin cofactor (RCoF) assay is used to evaluate VWF activity, but it does not assess collagen-binding activity. Normal values of RCoF and VWF antigen vary with ABO blood group type. The collagen-binding assay (CBA) measures VWF activity; however, its relationship with ABO blood group has not been completely explored. We performed CBA on plasma samples from 131 healthy volunteers to determine if CBA values correlated with blood type. Individuals with blood group O had a mean CBA value of 94 +/- 28%, which was significantly different from the mean of 117 +/- 33% in persons with non-O blood groups (P = 0.0001). Thus, CBA values appear to correlate with ABO blood type in a manner similar to RCoF. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410584     DOI: 10.1002/ajh.10238

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.

Authors:  V H Flood; J C Gill; P A Christopherson; J S Wren; K D Friedman; S L Haberichter; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

2.  Variables that Influence Platelet Function Analyzer-100™ Closure Times in Healthy Algerian Adults.

Authors:  Malika Belkacemi; Yassine Merad
Journal:  Int J Appl Basic Med Res       Date:  2021-07-19

Review 3.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.